Bright Minds Biosciences Inc. (DRUG)
| Market Cap | 254.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.62M |
| Shares Out | 6.97M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,929 |
| Open | 36.78 |
| Previous Close | 36.43 |
| Day's Range | 35.26 - 40.00 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 26, 2024 |
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with ... [Read more]
News
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of ...
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform tar...
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demons...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing no...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Bioscience...
Bright Minds is Unaware of Any Material Changes
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm ...
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnerin...
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on Septem...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. ...
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-cons...
Bright Minds Announces Effective Date of Share Consolidation
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing...
Bright Minds Announces Proposed Share Consolidation
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing...
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
-- BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B -- -- BMB-202 is the first clinical candidate f...
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" —
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization –
Bright Minds Biosciences Announces Non-Executive Director Appointment
David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare diseases David Weiner, MD, brings extensive experie...
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “De...
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification le...
Bright Minds Biosciences Announces Resignation of Board Member
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developi...
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Bright Minds Biosciences Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) --...